Search clinical trials for: Saxagliptin/metformin fixed-dose combination (FDC)

Total 197 results

AstraZeneca

Completed

Bioequivalence Study of Fixed-dose Combinations and Coadministered Individual Tablets of Saxagliptin/Metformin-Brazil

Type 2 Diabetes Mellitus

Brazil
Janssen-Cilag S.p.A.

Completed

An Italian Observation of Antiretroviral Treatment in Participants Taking Darunavir/ Cobicistat Plus Emtricitabine and Tenofovir Alafenamide Fumarate (DIAMANTE)

Human Immunodeficiency Virus (HIV)

Italy
University of Western Ontario, Canada
Pfizer

Completed

STITCH (Simplified Therapeutic Intervention To Control Hypertension)

Hypertension

Canada
International Union Against Tuberculosis and Lung...
United States Agency for International Development (USAID)

Unknown

Multicenter Trial for the Evaluation of a Fixed Dose Combined Tablet for the Treatment of Pulmonary Tuberculosis

Tuberculosis

Algeria, Bolivia, Colombia, Guinea, Mozambique, Nepal, Peru, Tanzania, Vietnam
Janssen Research & Development, LLC

Completed

Bioequivalence Study of Metformin Component of Fixed Dose Combination (FDC) Immediate Release (IR) Tablet of Canagliflozin and Metformin Compared to Metformin IR Tablet Co-administered With Canagliflozin in Healthy Fed and Fasted Participants

Bioequivalence

United States
Janssen Research & Development, LLC

Completed

Bioequivalence Study of Metformin Component of Canagliflozin and Metformin Fixed Dose Combination Immediate Release (IR) Tablet Comparing With Metformin IR Tablet Co-administered With Canagliflozin Tablet in Healthy Fed and Fasted Participants

Healthy

United States
Janssen Research & Development, LLC

Completed

A Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release With Respect to Metformin XR Tablet Coadministered With Canagliflozin in Healthy Fed and Fasted Participants

Healthy

United States
Janssen Research & Development, LLC

Completed

A Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release With Respect to Metformin Extended Release Tablet Coadministered With Canagliflozin in Healthy Fed and Fasted Participants

Healthy

United States
Janssen Research & Development, LLC

Completed

A Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release (XR) With Respect to Metformin XR Tablet Coadministered With Canagliflozin in Healthy Fed and Fasted Participants

Healthy

United States
Takeda

Completed

Efficacy and Safety of Alogliptin and Metformin Fixed-Dose Combination in Participants With Type 2 Diabetes

Diabetes Mellitus

China, Taiwan, Korea, Republic of, Malaysia
Merck Sharp & Dohme LLC

Completed

A Study to Demonstrate the Bioequivalence of Sitagliptin/Metformin Combination Tablets and Co-administration of Sitagliptin and Metformin as Individual Tablets (0431A-095)

Type 2 Diabetes
NewAmsterdam Pharma

Active, not recruiting

Investigating the Effect of Food on the Bioavailability of a Fixed Dose Combination of Obicetrapib and Ezetimibe

Healthy Volunteer Study

United States
Duke University
Gilead Sciences

Completed

Hepatitis C Virus(HCV) Heart and Lung Study

Heart Failure | Pulmonary Disease, Chronic Obstructive | Hepatitis C, Chronic | Lung Diseases, Interstitial

United States
AstraZeneca

Completed

Bioequivalence Study of 2.5-mg Saxagliptin and 500-mg Glucophage in Tablets and a Fixed-dose Combination Tablet in Healthy Participants

Type 2 Diabetes Mellitus

United States
GlaxoSmithKline

Completed

24-Hour Glycemia: Rosiglitazone Versus Glimepiride In Type 2 Diabetes

Non-Insulin-Dependent Diabetes Mellitus
Janssen Research & Development, LLC

Completed

A Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release With Respect to Metformin XR Tablet Co-administered With Canagliflozin in Healthy Fed and Fasted Participants

Healthy

United States
Merck Sharp & Dohme LLC

Completed

A Study to Demonstrate the Bioequivalence of Sitagliptin/Metformin Combination Tablets and Concomitant Administration of Sitagliptin and Metformin as Individual Tablets (0431A-048)

Type 2 Diabetes
AstraZeneca

Completed

Bioequivalence Study of Combination Tablets of Saxagliptin / Dapagliflozin / Metformin XR (Extended-release) and Dapagliflozin / Metformin XR Relative to Individual Components in Healthy Subjects

Type 2 Diabetes Mellitus

United Kingdom
ANRS, Emerging Infectious Diseases
Gilead Sciences; Ministry of Health, Thailand; Assistance Publique - Hôpitaux... and other collaborators

Not yet recruiting

Efficacy, Acceptability and Safety of Event-driven HIV PrEP Using TAF/FTC in MSM in Thailand and France. (SimpPrEP)

HIV/AIDS

France, Thailand
AstraZeneca

Completed

Bioequivalence Study of Fixed Dose Combination of 2.5 mg Saxagliptin/850 mg Metformin Tablet Relative to 2.5 mg Onglyza and 850 mg Glucophage Tablets Co-Administered

Type 2 Diabetes Mellitus

United States
Merck KGaA, Darmstadt, Germany

Completed

Bioequivalence and Drug - Drug Interaction Study of Metformin/Gliclazide in Healthy Participants

Healthy

Germany
GL Pharm Tech Corporation

Completed

Pharmacokinetic Characteristics of GLH1SM Extended Release Tablets in Healthy Volunteers

Healthy

Korea, Republic of
Merck KGaA, Darmstadt, Germany

Completed

A Study to Assess the Food Effect on Bioavailability of Metformin/Gliclazide in Healthy Participants

Healthy

Mexico
GL Pharm Tech Corporation

Completed

Pharmacokinetic Characteristics of GLH1SM Extended Release Tablets in Healthy Volunteers(Fed)

Healthy

Korea, Republic of
AstraZeneca

Completed

Bioequivalence Study of the Fixed Dose Combination of 5 mg Saxagliptin and 500 mg Metformin XR Tablet (Manufactured in Mt Vernon, IN) Relative to 5 mg Saxagliptin Tablet and 500 mg Metformin XR Tablet (Manufactured in Evansville, IN)

Diabetes Mellitus

United States
Johnson & Johnson Private Limited

Completed

A Study to Assess Safety of Canagliflozin and Metformin Hydrochloride Combination Given as a Supplement to Diet and Exercise to Improve Blood Sugar Level in Indian Adult Participants With Diabetes

Diabetes Mellitus

India
Rockefeller University
National Institute on Drug Abuse (NIDA)

Completed

Immunologic Effects of HCV Therapy With HARVONI in HCV Genotype 1 Chronically Mono-infected Active and Former IDUs

Hepatitis C

United States
Nanjing First Hospital, Nanjing Medical University

Not yet recruiting

Effect of Metformin, Dapagliflozin, Combination of Metformin and Pioglitazone in Patients With Type 2 Diabetes

Insulin Resistance | Type2diabetes
AstraZeneca

Completed

Bioequivalence Study of the Fixed Dose Combination of 5 mg Saxagliptin/1000 mg Metformin XR (Manufactured in Mt Vernon, IN) Relative to 5 mg of Onglyza and 2 × 500 mg Glucophage XR

Diabetes Mellitus

United States
Melanoma Institute Australia
Bristol-Myers Squibb

Recruiting

A Phase 2 Clinical Trial of Neoadjuvant Relatlimab and Nivolumab in High Risk, Clinical Stage II Cutaneous Melanoma (Neo ReNi II)

Stage II Melanoma

Australia
Janssen Research & Development, LLC

Completed

A Study to Assess the Bioequivalence of 2 Fixed Dose Combination Tablets of Canagliflozin and Metformin Immediate Release (IR) With Respect to the Individual Components of Canagliflozin and Metformin IR Tablets in Healthy Volunteers

Healthy

United States
AstraZeneca

Completed

Bioequivalence Study of Saxagliptin and Glucophage Combination Formulations in Healthy Subjects (B)

Type 2 Diabetes Mellitus

United States
Bristol-Myers Squibb

Completed

To Assess the Effect of Renal Impairment on the Blood Levels of Daclatasvir (DCV), Asunaprevir (ASV) and BMS-791325 After Multiple Doses of a Fixed Dose Combination Tablet

Hepatitis C

United States
AstraZeneca

Terminated

Study of Saxagliptin, 5-Hydroxy Saxagliptin, and Metformin Concentrations/Levels in Pediatric Subjects With T2DM

Type 2 Diabetes Mellitus

United States
Merck Sharp & Dohme LLC

Completed

Sitagliptin/Metformin Fed Bioequivalence Study (0431A-080)

Type 2 Diabetes Mellitus
Fakultas Kedokteran Universitas Indonesia

Recruiting

Proportion of Clinical Improvement & Type 1 Interferon (IFN) Score Changes in Idiopathic Uveitis Patients With Interferon Gamma Release Assay (IGRA) Positive

Anti-Tuberculous Drug Reaction | Tuberculous Uveitis | Tuberculosis; Uveitis (Manifestation)

Indonesia
Merck Sharp & Dohme LLC

Completed

Efficacy and Safety of Sitagliptin/Metformin Fixed-Dose Combination (FDC) Compared to Glimepiride in Participants With Type 2 Diabetes Mellitus (MK-0431A-202)

Type 2 Diabetes Mellitus
The Catholic University of Korea
Bayer

Completed

Study to Evaluate the Efficacy of Acarbose,Metformin,Sitagliptin Combination Treatment in DM Patients

Type 2 Diabetes Mellitus

Korea, Republic of
Boehringer Ingelheim
Eli Lilly and Company

Completed

Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Linagliptin/Metformin Extended Release Compared With Single Tablets

Healthy

Germany
AstraZeneca

Withdrawn

BE Study of the Fixed Dose Combination of 5 mg Saxagliptin and 500 mg Metformin HCl XR Tablet Relative to a 5 mg Saxagliptin (Onglyza™) Tablet and a 500 mg Metformin HCl XR (Glifage® XR Marketed in Brazil by Merck S.A.) Tablet Co-Administered to Healthy Subjects in the Fasted and Fed States

Type 2 Diabetes

Brazil
Korea University Anam Hospital
AstraZeneca

Unknown

Effectiveness & Tolerability of Novel, Initial Triple Combination Therapy vs Conventional Therapy in Type 2 Diabetes

Diabetes Mellitus, Type II

Korea, Republic of
University Hospital, Clermont-Ferrand
Merck Sharp & Dohme LLC

Completed

Study to Investigate the Efficacy of Elbasvir/Grazoprevir Fixed-Dose Combination for 8 Weeks in Treatment-Naïve, HCV GT1b-Infected Patients, With Non-severe Fibrosis (STREAGER)

Chronic HCV Infection

France
Genentech, Inc.

Approved for marketing

An Expanded Access Study to Provide at Home Subcutaneous Administration of Pertuzumab and Trastuzumab Fixed-Dose Combination (PH FDC SC) for Patients With HER2-Positive Breast Cancer During the COVID-19 Pandemic

HER2-positive Breast Cancer

United States
Hoffmann-La Roche

Completed

A Study to Evaluate Patient Preference and Satisfaction of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Participants With HER2-Positive Early Breast Cancer (PHranceSCa)

HER2-Positive Early Breast Cancer

United States, Finland, Hong Kong, Panama, Portugal, Spain, Mexico, Sweden, Brazil, Serbia, Argentina, Lebanon, Cuba, Qatar, Saudi Arabia, Chile, Jordan
Seoul National University Bundang Hospital

Completed

Therapeutic Efficacy of Triple Combination in Drug-naïve Korean Type 2 Diabetic Patients

Type 2 Diabetes

Korea, Republic of
Handok Inc.

Completed

Study Comparing Efficacy and Safety of Amaryl M and Metformin Uptitraion to Type 2 DM

Type 2 Diabetes Mellitus

Korea, Republic of
Timothy Morgan, MD
Bristol-Myers Squibb; National Cancer Institute (NCI); VA Long Beach Healthcare...

Completed

Rapid Hepatitis C Elimination Trial- A Pilot Study of Daclatasvir/Asunaprevir/BMS-791325 With or Without Ribavirin To Treat Hepatitis C Virus (RHACE 1)

Hepatitis C

United States
AstraZeneca

Completed

Food Interaction Study To Assess the Effect of Food on the Pharmacokinetics of Esomeprazole 20 mg/Acetylsalicylic Acid 81 mg

Pharmacokinetics | Effect of Food

United States
Institute Of Cardiology & Internal Diseases, Kazakhstan
Merck Sharp & Dohme LLC; Synergy Research Group

Unknown

Open-Label Efficacy and Safety Study of the Elbasvir/ Grazoprevir Fixed Dose Combination Patients With Chronic HCV GT1b

Metabolic Syndrome | Fibrosis, Liver | Cirrhoses, Liver | Chronic Hepatitis C Genotype 1B

Kazakhstan
Massachusetts General Hospital
Merck Sharp & Dohme LLC

Completed

Preemptive Treatment With Grazoprevir and Elbasvir for Donor HCV Positive to Recipient HCV Negative Kidney Transplant

Renal Failure

United States

3

Subscribe